Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;58(Suppl 2):60-63.
doi: 10.20471/acc.2019.58.s2.09.

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY

Marko Boban  1
Affiliations
Review

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY

Marko Boban. Acta Clin Croat. 2019 Nov.

Abstract

The leading cause of death in patients with prostate cancer are cardiovascular diseases. Androgen deprivation therapy is the mainstay of treatment in prostate cancers. The latter has numerous perplexed disadvantaging effects to cardiovascular health. ADT alternates the metabolic profile, insulin resistance and glucose metabolism, causes loss of lean body mass, an increase in adipose tissue, obesity, worsening of atherosclerosis and heart failure. It is important to point out that prostate cancer survivors have increased prevalence of coronary artery disease, cerebrovascular stroke, myocardial infarctions and cardiovascular mortality. Due to these reasons particular care on prevention and treatment of cardiovascular diseases should become a standard of care in patients with prostate cancer.

Keywords: Androgen Deprivation Therapy (ADT); Cardiovascular Diseases; Myocardial Infarction; Prostate Cancer.

PubMed Disclaimer

References

    1. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–500. 10.1002/cncr.22933 - DOI - PubMed
    1. Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc. 2009;57:24–30. 10.1111/j.1532-5415.2008.02091.x - DOI - PMC - PubMed
    1. D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–5. 10.1200/JCO.2006.09.3369 - DOI - PubMed
    1. Chen DY, See LC, Liu JR, Chuang CK, Pang ST, Hsieh IC, et al. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study. J Clin Oncol. 2017;35:3697–705. 10.1200/JCO.2016.71.4204 - DOI - PubMed
    1. Jin C, Fan Y, Meng Y, Shen C, Wang Y, Hu S, et al. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients. Prostate Cancer Prostatic Dis. 2016;19:333–9. 10.1038/pcan.2016.35 - DOI - PubMed

LinkOut - more resources